Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. - Wikidata - awgldk - TriplyDB

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

http://www.wikidata.org/entity/Q33368655

about

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis Induced-fit mechanism for prolyl endopeptidase.Design and synthesis of 4-(2,4,5-trifluorophenyl)butane-1,3-diamines as dipeptidyl peptidase IV inhibitors Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions Regulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26 Marine Organisms with Anti-Diabetes Properties Saxagliptin overview: special focus on safety and adverse effects Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4.Grassypeptolides as natural inhibitors of dipeptidyl peptidase 8 and T-cell activation.The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses The nonglycemic actions of dipeptidyl peptidase-4 inhibitors Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes.Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides.Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8.Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.Clinical pharmacokinetics and pharmacodynamics of linagliptin.Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity.Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y₁ and Y₂ receptors Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins Identification of a gene involved in the synthesis of a dipeptidyl peptidase IV inhibitor in Aspergillus oryzae Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats.Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model

P2860

Q26778329-85245564-8DFD-4C7B-BE9A-32388A3A5541 Q26785454-0EB7EFDB-0118-40A1-AE42-89FC1373C530 Q26795473-3D3C7BEF-86A0-4A90-9FD5-1B2290C61326 Q27661330-1A92531E-6BD8-4E97-9323-1D6218A56E45 Q27684616-6D0F4984-2762-4BED-81FF-958B5559A0DE Q27701492-A346BA37-0D5B-458F-B00B-A5707AF97809 Q28072580-F645D21A-43F3-450A-8B8A-0D7C83A1CEE0 Q28073250-ADDA0C16-A78A-4BAD-A4EB-ADBD98767FDB Q28278863-6B13DE95-8A4E-49F1-A3D4-E478AB26B67A Q28762629-61310F24-E2FD-43F4-A653-A32CDD399E56 Q33231553-2489AC0F-5E2C-4FA2-97D9-43EAF40A03B5 Q33237060-44405ECB-4723-4614-AA77-F30D34473591 Q33428789-FB391786-2BE0-4C99-B07E-01B23A7B5E3C Q33671491-12ABB15E-CE00-4EE5-A8E4-75ACC2058A5E Q33728657-9EC1CEDB-30B1-4058-A485-79154CCBDD95 Q33849176-CE4A2C33-4161-42CC-B8FC-1C06B526DFE6 Q33931373-AB1DF480-AFF0-4108-AE79-BF0533ABDB74 Q34029715-8BE3D43B-92F5-41A6-AA5C-5EDD513EC80C Q34063707-B9C754C2-B91E-4514-B830-D71084B07294 Q34135837-F549029D-CCC6-4436-ABDE-95495DC43306 Q34198223-4E2A71AC-1309-4616-8732-9AC157502E6F Q34268925-C13999D0-F9D8-4302-9555-85FD57E54446 Q34278297-CE2EC3A9-C560-422E-948F-4525135F1804 Q34573849-B8620686-9CFD-4839-AD23-FA1D3CC44BF5 Q34589793-B3E4A6F4-2535-41F7-A96C-BB8F0BF06011 Q34638128-ED615C16-016E-4995-9C4A-9CF02583CF95 Q35026483-675E2132-23D6-49EB-93B2-3C496447F5B0 Q35040181-CE696D8F-7EE0-4904-8170-7A5BDE35B5D0 Q35067242-D5EF165D-988D-43D6-AA62-EAA132081943 Q35131941-CC8081B7-8779-4037-AE67-534A9A726F4C Q35201777-247DAF58-3FF4-42ED-A191-F01D5F934A8F Q35287265-2D100245-D777-44DA-8978-76793451003F Q35693453-3D779C62-0908-4AE4-A9CF-CCCD90EE87A5 Q35808043-6B511CFE-C377-4B73-B9DA-72AB36D99D3A Q35916947-859FB0F8-64D2-4F2D-8CDB-7CAA705F7057 Q36058025-3BAC99B6-912A-4CE2-96CB-4E43E2B3F083 Q36110846-51325395-1F7E-40B6-8A0B-696CB537D4DE Q36277224-1608A8E3-BCD3-4704-A741-CB658F518B5A Q36332490-AFAFFB89-0C20-4AFF-AE3C-517A29AB75C8 Q36470223-F4EFDF1B-EEC7-4CD8-A6A0-5A6945D12CE8

P2860

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

http://www.wikidata.org/entity/Q33368655

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Dipeptidyl peptidase IV inhibi ...... dipeptidyl peptidases 8 and 9.

@ast

Dipeptidyl peptidase IV inhibi ...... dipeptidyl peptidases 8 and 9.

@en

type

label

Dipeptidyl peptidase IV inhibi ...... dipeptidyl peptidases 8 and 9.

@ast

Dipeptidyl peptidase IV inhibi ...... dipeptidyl peptidases 8 and 9.

@en

prefLabel

Dipeptidyl peptidase IV inhibi ...... dipeptidyl peptidases 8 and 9.

@ast

Dipeptidyl peptidase IV inhibi ...... dipeptidyl peptidases 8 and 9.

@en

P1433

Q33368655-B4202613-A3B1-4D12-A561-A7F61F6AF67F

P1476

Q33368655-DB17737D-901B-4C4F-B173-7C515479F539

P2093

Q33368655-0718E36B-3448-4E2E-8113-85E15F1C5906

Q33368655-0A34D1AD-1ED6-460F-9194-546D476BCA9C

Q33368655-0E69567F-F297-4C69-8F25-DF048CE35CC1

Q33368655-0F816B72-FEBF-49E9-8ADE-14CDE7BDFE9A

Q33368655-0FC99FFA-6972-4AEF-9E8D-108FE6162DAD

Q33368655-122F308A-C6E1-42BC-8E99-389A5C823ED0

Q33368655-14925BCE-5DC7-43AD-8A71-61A11118D7FE

Q33368655-20A9FF2B-8E8B-44FA-9C56-F71486B26ADB

Q33368655-3181E20A-5859-4A88-8CBC-4CCF5B7C203C

Q33368655-3616D929-A8CB-402A-862C-3F46F1A8C136

P304

Q33368655-D711D949-DFF3-4345-93BD-9EFC7ACA8363

P31

Q33368655-803E4D94-63F3-4855-8DD7-631F8409E4B7

P356

Q33368655-55B543C4-01CE-428A-9901-EFB0903B96B6

P407

Q33368655-764BE0C1-6102-4532-8DB6-5101E9C3B0CC

P433

Q33368655-6DCCEE01-A509-438F-A6F9-0B625FBB888C

P478

Q33368655-C4E3BE66-6983-4C17-966C-F6AE5B4114A8

P577

Q33368655-E82FDEEF-928C-492E-8F0D-43BF3F32D66C

P5875

Q33368655-195DE4A4-26CE-4539-B320-3257D764F27B

P698

Q33368655-621924CA-77E3-4562-8CE9-B690F9944867

P921

Q33368655-E58DD9D5-4686-47CF-BB92-3BD8CD0D1A86

P356

DIABETES.54.10.2988

P1433

P1476

Dipeptidyl peptidase IV inhibi ...... dipeptidyl peptidases 8 and 9.

@en

P2093

Aleksandr N Petrov

http://www.w3.org/2001/XMLSchema#string

Andrea Woods

http://www.w3.org/2001/XMLSchema#string

Ann E Weber

http://www.w3.org/2001/XMLSchema#string

Barbara Leiting

http://www.w3.org/2001/XMLSchema#string

Chi-Chung Chan

http://www.w3.org/2001/XMLSchema#string

Dawn E Ippolito

http://www.w3.org/2001/XMLSchema#string

Dennis Zaller

http://www.w3.org/2001/XMLSchema#string

Dooseop Kim

http://www.w3.org/2001/XMLSchema#string

George J Eiermann

http://www.w3.org/2001/XMLSchema#string

George R Lankas

http://www.w3.org/2001/XMLSchema#string

P304

2988-2994

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIABETES.54.10.2988

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7578809

http://www.w3.org/2001/XMLSchema#string

P698

16186403

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes